Company Overview
Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies. We are advancing an innovative portfolio of therapeutics, supported by a leadership team with deep experience in the design, development, and commercialization of cutting-edge therapies, including antibody-drug conjugates. Our pipeline includes varegacestat, an investigational gamma secretase inhibitor for which an NDA has been accepted by the U.S. FDA; IM-1021, a clinical-stage ROR1 ADC; IM-1617, a clinical-stage solid tumor ADC; and IM-3050, a clinical-stage FAP-targeted radioligand therapy. We are also advancing a broad portfolio of early-stage ADCs pursuing undisclosed solid tumor targets.
Position Overview
Immunome is seeking a highly experienced and strategic National Account Director, Enterprise Access to lead integrated account strategy across a U.S. national footprint in support of our oncology portfolio. This role will build and sustain relationships with national and regional health plans, pharmacy benefit managers (PBMs), and Key Account customer networks to advance launch readiness, appropriate coverage and reimbursement, formulary access, and therapeutic adoption following regulatory approval.
The successful candidate will bring deep expertise in payer access and institutional purchasing, recognizing the distinct operating models, decision processes, and account economics of each. This position combines direct account ownership, strategic negotiation, and executive relationship management with cross-functional leadership, serving as a primary resource for field teams and connecting headquarters strategy with local execution.
Responsibilities
Strategic Leadership
Develop and execute multi-year Payer / PBM and Key Account institution plans with defined access objectives, stakeholder engagement, procurement strategies, and measures of success.
Apply commercial, Medicare Part D, and Medicaid expertise alongside community and integrated delivery network (IDN) business acumen, tailoring strategies to payer coverage decisions and provider purchasing structures.
Translate oncology market trends, clinical differentiation, reimbursement, and clinical pathway dynamics into national account priorities and commercial planning.
Payer Access and Stakeholder Management
Build executive-level relationships with pharmacy directors, medical directors, clinical leaders, and pharmacy and therapeutics (P&T) decision-makers across national and regional health plans and PBMs.
Navigate formulary and preferred drug list (PDL) development, utilization management, and coverage and reimbursement policies across commercial plans, Medicare Part D, and Medicaid fee-for-service (FFS) programs and managed care organizations (MCOs).
Map decision authority and payer affiliates; coordinate internal account teams to identify access barriers, align engagement, and advance appropriate coverage outcomes.
Institutional Access and Stakeholder Management
Build relationships with CEOs, CFOs, COOs, medical directors, pharmacists, and practice administrators across oncology customers and their member organizations.
Extend engagement to IDNs, health systems, hospital and community oncology networks, and national clinical pathway organizations, aligning corporate relationships with local customer needs.
Use approved clinical and economic evidence to support appropriate preferred formulary and pathway positioning with relevant provider and pathway decision-makers, respecting independent clinical decisions.
Strategic Negotiation
Lead payer, PBM, and community account strategy and negotiations, including pull-through opportunity, within approved authority; balance coverage and purchasing objectives, rebate commitments, pricing dynamics, and long-term business value.
Partner with Market Access, Finance, Legal, and Compliance to evaluate contract economics, 340B considerations, and Medicaid Best Price implications…